7. Hypersensitivity
reactions (including
skin reactions and
urticaria)
Hypothyroidism
Hyperthyroidism
Dehydration
Acute respiratory
distress, etc)
Gastro oesophageal
reflux disease
Pancreatitis
Gastritis
Increase in bilirubin
Jaundice
Eczema
Keratoacanthoma /
squamous cell cancer
of the skin
8. Recommended Daily Dose
Nexavar should be taken
without food or together
with a low- or moderate-fat
meal.
Patients who intend to have
a high-fat meal should take
Nexavar at least 1 hour
before or 2 hours after the
meal.
The tablets should be taken
with a glass of water.
400 mg (2 x 200 mg
tablets) twice daily
9. Levels of sorafenib may be
increased in patients with
severe hepatic impairment.
10. Nexavar is not recommended for use in
Pregnant women
Women who are breastfeeding.
Children and adolescents (<18 years) due to
lack of data.
Temporary interruption of sorafenib therapy
is recommended in patients undergoing
major surgical procedures.
11. Treatment should continue as long
as clinical benefit is observed or
until unacceptable toxicity occurs.
12. Sorafenib is a multi-kinase inhibitor
Small molecular inhibitor of
Raf kinase
PDGF (platelet-derived growth factor)
VEGF receptor 2 & 3 kinases and c Kit the
receptor for Stem cell factor
Simultaneously targets Raf/Mek/Erk
pathway
13.
14. Preclinical studies suggest that sorafenib
acts on tumors and tumor vasculature
By inhibiting cellular proliferation and
angiogenesis
and/or
By inducing apoptosis
In most tumor types, sorafenib inhibited
signaling through Raf
As evidenced by reduced pERK levels
16. In a study of 602 people
Nexavar helped slow cancer growth
and extend the lives of patients
compared with patients who did not
receive Nexavar
Nexavar extended overall survival by
44%.